ECSP045277A - Composición oftálmica que comprende ascomicina - Google Patents

Composición oftálmica que comprende ascomicina

Info

Publication number
ECSP045277A
ECSP045277A EC2004005277A ECSP045277A ECSP045277A EC SP045277 A ECSP045277 A EC SP045277A EC 2004005277 A EC2004005277 A EC 2004005277A EC SP045277 A ECSP045277 A EC SP045277A EC SP045277 A ECSP045277 A EC SP045277A
Authority
EC
Ecuador
Prior art keywords
ascomycin
ophthalm
composition
blepharitis
treatment
Prior art date
Application number
EC2004005277A
Other languages
English (en)
Inventor
Saunier Maggy Babiole
Jean Claude Bizec
Michelle Pikhan Wong
Shau-Fong Yen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27791682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045277(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP045277A publication Critical patent/ECSP045277A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invención se refiere a composiciones oftálmicas tópicas, las cuales comprenden una ascomicina, por ejemplo, para el tratamiento de enfermedades inflamatorias, tales como blefaritis.
EC2004005277A 2002-03-04 2004-09-03 Composición oftálmica que comprende ascomicina ECSP045277A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36151502P 2002-03-04 2002-03-04
US40927502P 2002-09-09 2002-09-09

Publications (1)

Publication Number Publication Date
ECSP045277A true ECSP045277A (es) 2004-10-26

Family

ID=27791682

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005277A ECSP045277A (es) 2002-03-04 2004-09-03 Composición oftálmica que comprende ascomicina

Country Status (27)

Country Link
US (4) US20050220823A1 (es)
EP (1) EP1482936B1 (es)
JP (1) JP4740542B2 (es)
KR (1) KR100992948B1 (es)
CN (1) CN1297270C (es)
AR (1) AR038628A1 (es)
AT (1) ATE341326T1 (es)
AU (1) AU2003218679B2 (es)
BR (1) BR0308184A (es)
CA (1) CA2477769C (es)
CO (1) CO5611133A2 (es)
DE (1) DE60308836T2 (es)
DK (1) DK1482936T3 (es)
EC (1) ECSP045277A (es)
EG (1) EG24403A (es)
ES (1) ES2274214T3 (es)
IL (2) IL163657A0 (es)
MX (1) MXPA04008571A (es)
MY (1) MY137563A (es)
NO (1) NO20044092L (es)
NZ (1) NZ534690A (es)
PE (1) PE20030828A1 (es)
PL (1) PL210870B1 (es)
PT (1) PT1482936E (es)
RU (1) RU2322982C2 (es)
TW (1) TW200305437A (es)
WO (1) WO2003074054A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295647T3 (es) 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
CA2492989C (en) * 2002-07-23 2012-11-20 Novartis Ag Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
BRPI0705564B8 (pt) * 2007-10-10 2021-05-25 Embrapa Pesquisa Agropecuaria sistema do tipo cristal líquido contínuo contendo co-solvente portador de substâncias fracamente solúveis em água, seu processo de obtenção e seus usos
EP2238878A1 (en) 2009-04-09 2010-10-13 Nestec S.A. Beverage preparation device having a closing mechanism with force demultiplying means
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
EP2962688B1 (en) 2009-05-12 2020-06-24 Galenica AB Oil-in-water emulsion of mometasone and propylene glycol
JP5779591B2 (ja) * 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド Ａｂｔ−２６３カプセル剤
RU2437647C2 (ru) * 2010-02-27 2011-12-27 Пшеничников Виталий Георгиевич Фармацевтическая композиция, обладающая антибактериальным, противовирусным и противогрибковым действием
WO2011127151A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014153733A1 (en) * 2013-03-27 2014-10-02 Comprehensive Drug Enterprises, Ltd. Ophthalmic composition, method for preparing the same, and use of the same
US11103464B2 (en) * 2013-11-29 2021-08-31 Rohto Pharmaceutical Co., Ltd. Aqueous composition for ophthalmological use or otolaryngological use
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US10606760B2 (en) * 2017-08-23 2020-03-31 Samsung Electronics Co., Ltd. Nonvolatile memory devices and methods of controlling the same
EP3741367A1 (en) * 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
TW202432089A (zh) * 2023-01-31 2024-08-16 溫士頓醫藥股份有限公司 一種滴眼油劑型的醫藥組合物
WO2024209038A1 (en) 2023-04-06 2024-10-10 Premark Pharma Gmbh Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU635286B2 (en) * 1989-07-05 1993-03-18 Astellas Pharma Inc. Aqueous liquid composition for external use
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
AU680813B2 (en) * 1992-08-28 1997-08-14 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
CA2146006C (en) * 1993-08-18 2004-10-12 Louis Desantis, Jr. Use of ergoline derivatives for the treatment of glaucoma
CA2201134A1 (en) * 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
ATE214593T1 (de) * 1994-10-26 2002-04-15 Novartis Erfind Verwalt Gmbh Verwendung eines ungesättigten fettalkohols
FR2732598B1 (fr) * 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
US6096785A (en) * 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
FR2755852B1 (fr) * 1996-11-15 1998-12-24 Oreal Utilisation d'un alkylether de glycerol dans une composition cosmetique et/ou dermatologique comme actif pour le traitement de la seborrhee et de l'acne
CA2326222C (en) * 1998-04-27 2008-09-23 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
AU777915B2 (en) * 1999-04-30 2004-11-04 Sucampo Ag Use of macrolide compounds for the treatment of dry eye

Also Published As

Publication number Publication date
AR038628A1 (es) 2005-01-19
US20050220823A1 (en) 2005-10-06
CO5611133A2 (es) 2006-02-28
IL163657A0 (en) 2005-12-18
DE60308836D1 (de) 2006-11-16
US20120015971A1 (en) 2012-01-19
NZ534690A (en) 2007-06-29
KR20040094718A (ko) 2004-11-10
CA2477769A1 (en) 2003-09-12
RU2322982C2 (ru) 2008-04-27
BR0308184A (pt) 2005-01-11
KR100992948B1 (ko) 2010-11-08
PL370917A1 (en) 2005-06-13
NO20044092L (no) 2004-09-27
PE20030828A1 (es) 2003-11-04
AU2003218679B2 (en) 2007-04-05
MY137563A (en) 2009-02-27
IL163657A (en) 2009-11-18
CA2477769C (en) 2011-01-18
JP2005529851A (ja) 2005-10-06
MXPA04008571A (es) 2004-12-06
EP1482936B1 (en) 2006-10-04
TW200305437A (en) 2003-11-01
PT1482936E (pt) 2007-01-31
JP4740542B2 (ja) 2011-08-03
WO2003074054A1 (en) 2003-09-12
ATE341326T1 (de) 2006-10-15
US20100113501A1 (en) 2010-05-06
PL210870B1 (pl) 2012-03-30
EP1482936A1 (en) 2004-12-08
DK1482936T3 (da) 2007-01-08
RU2004129593A (ru) 2005-09-10
CN1297270C (zh) 2007-01-31
HK1071301A1 (en) 2005-07-15
ES2274214T3 (es) 2007-05-16
US20110152307A1 (en) 2011-06-23
EG24403A (en) 2009-04-29
CN1638769A (zh) 2005-07-13
AU2003218679A1 (en) 2003-09-16
DE60308836T2 (de) 2007-04-26

Similar Documents

Publication Publication Date Title
ECSP045277A (es) Composición oftálmica que comprende ascomicina
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
HN2003000417A (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CR8919A (es) Analogos de tetrapeptidos
PA8640701A1 (es) Indazoles utiles para tratamiento de enfermedades cardiovascular
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
UY30723A1 (es) Compuestos de biciclocarboxiamida sustituidos
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY37971A (es) Derivados de indol macrocíclicos sustituidos
CO6612202A2 (es) Inhibidores heterparílicos bicíclicos de pde4
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
CR8636A (es) Compuestos utiles para el tratamiento de enfermedades
ECSP056006A (es) Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas
CR8574A (es) Compuestos silinano como inhibidores de cisteina proteasa
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
PA8616901A1 (es) Metodos y composiciones para la inhibicion de selectina